Coverage dated October 18, 2021 to October 22, 2021
FDA Says Pfizer COVID Vaccine Looks Effective for Young Kids
Headline from NBC4 Washington, on the newest of 2 developments
Federal health regulators said late Friday that kid-size doses of Pfizer’s COVID-19 vaccine appear highly effective at preventing symptomatic infections in elementary school children and caused no unexpected safety issues, as the U.S. weighs beginning vaccinations in youngsters.
NBC4 Washington's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
Pfizer vaccine is 93% effective in preventing COVID-19 hospitalization among adolescents, CDC study finds
Headline from Local News 8 ·
Newest
FDA Says Pfizer COVID Vaccine Looks Effective for Young Kids
The Pfizer/BioNTech vaccine is 93% effective in preventing hospitalization due to COVID-19 among children ages 12 to 18, according to a study by the US Centers for Disease Control and Prevention. Vaccine effectiveness differed only slightly within that age group, with 91% effectiveness for children …
The Pfizer-BioNTech COVID-19 vaccine has been found to be 93 percent effective against hospitalization for 12 to 18 year olds, according to Centers for Disease Control and Prevention (CDC) research from when th
The Pfizer/BioNTech COVID-19 vaccine is 93% effective against COVID-19 hospitalization in youth, according to a U.S. Centers for Disease Control and Prevention study.
Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers
Pfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing symptomatic infections in elementary school children.
Pfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing symptomatic infections in elementary school children
Kid-size doses of the Pfizer BioNTech COVID-19 vaccine appear to be safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday.
FDA expected to weigh in on findings, which also show shot to be safe for smaller kids, later Friday, with child-sized doses possibly available starting as early as next month
In a new document posted ahead of a key meeting of the US Food and Drug Administration's vaccine advisers, Pfizer says its vaccine is safe and 90.7% effective against symptomatic Covid-19 in children ages 5 to 11.
The authorization of a vaccine for school-aged children would open coronavirus vaccine eligibility to an estimated 28 million children in the United States.
A study released Friday found that kid-size doses of Pfizer’s Covid vaccine are nearly 91 percent effective at preventing symptomatic infections in 5- to 11-year-olds.
Smaller doses of Pfizer's COVID-19 vaccine for children ages 5 to 11 appear safe and are nearly 91 percent effective at preventing symptomatic disease, the company said in a study released Friday.
